Beam Widens Loss as Pivotal Gene-Editing Trial Advances
Beam Therapeutics reported a net loss of $122.7 million for the second quarter as it drew $200 million from its credit facility to fund a widening clinical pipeline.
Beam Therapeutics (BEAM) reported a net loss of $122.7 million, or $1.18 a share, for the second quarter of 2026, widening from a loss of $102.1 million, or $1.00 a share, a year earlier. The gene-editing company's loss grew even as it advanced its lead pivotal program and cleared an investigational new drug application for a second, faster-moving one.
The widening loss came largely from the revenue side rather than spending. License and collaboration revenue collapsed to $490 thousand from $8.466 million a year earlier, a decline of about 94%. Research and development expenses actually fell 6.6% to $95.1 million from $101.8 million, reflecting program completions and shifting trial phases, while general and administrative costs rose 18.6% to $31.9 million. The net effect was a wider loss despite lower core research spending.
Beam's cash, cash equivalents and marketable securities fell to $1.15 billion as of June 30 from $1.245 billion at the end of 2025, a decrease of roughly $92 million over the first half of the year. Total liabilities rose 31% to $318.9 million from $242.8 million over the same period, while stockholders' equity fell to $1.067 billion from $1.238 billion. The company disclosed plans to draw $200 million from its Sixth Street credit facility, a step aimed at extending its cash runway into mid-2029. That runway guidance has held at mid-2029 across the past three quarterly releases even as the underlying cash balance declined, and the facility was cited only in general terms before this quarter's specific draw amount.
Beam's clinical calendar showed the clearest signs of progress. The company said the first patient was dosed in the global pivotal cohort of BEAM-302 in July 2026, after guiding in the first quarter that the cohort was merely expected to initiate in the second half of the year. That puts the base-editing program for alpha-1 antitrypsin deficiency on track heading into its registrational phase.
In hematology, Beam said dosing was complete for all adult and adolescent patients in the BEACON study of risto-cel, its sickle cell program, moving the trial past the enrollment stage that spanned the prior two quarters. The company kept its guidance for a biologics license application submission at "as early as year-end 2026" unchanged across all four of the periods reviewed, a consistency that stands out against the accelerating clinical timeline.
Beam's phenylketonuria program, BEAM-304, moved faster than the company had previously guided. An IND clearance arrived in June 2026 and clinical start-up work is now underway, ahead of the "IND filing anticipated in 2026" language the company used as recently as its fourth-quarter 2025 release. A smaller program, BEAM-103, an anti-CD117 monoclonal antibody, also cleared a milestone, with the company reporting that Phase 1 healthy-volunteer dosing was complete and well tolerated across all doses, up from a first-subject-dosed disclosure in the prior release.
The company's public characterization of its cash position grew less precise even as the pipeline accelerated. Beam described its balance as "$1.2 billion" in both the first- and second-quarter releases, a rounder figure than the $1.1 billion reported for the third quarter of 2025 or the $1.25 billion estimate given at year-end, even though the underlying balance sheet shows a sequential decline from $1.245 billion to $1.153 billion. The $200 million credit facility draw disclosed this quarter is intended to offset that decline as multiple programs move into pivotal and later-stage testing.